Drug Trial Radar · NCT02497898
Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Jul 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Jul 2015
Primary completion
Jul 2038
Study completion Jul 2040
Sponsor
- Lead sponsor
- The First People's Hospital of ChangzhouAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 15, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.
Conditions
- Lymphoma, Non-Hodgkin
Interventions
Cytokine-induced killer cells (CIK)Biological
Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free-Survival (PFS)Time frame: 1 month
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.